RxDoctor Payments DataLook up a doctor →

Jayant Pinto

Otolaryngology · Chicago, ILNPI 1891850624

Payments from drug & device makers

$747,231in general payments, 2019–2025

Across 556 payments — averaging $1343.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$301K
  • Regeneron Healthcare Solutions, Inc.$270K
  • Optinose US, Inc.$83K
  • Regeneron$60K
  • Insmed, Inc.$12K
  • GSK$6K
  • plus $16K from 11 others
$10,093in research payments, 2019–2025

Across 15 payments — averaging $672.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$10K

What the payments were for

  • Consulting fees$41,5517%
  • Speaking & faculty fees$521,01583%
  • Travel & lodging$57,6539%
  • Food & beverage$7,5701%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$747,231 in reported general payments places this provider in the 95th percentile of 390 otolaryngology providers in Illinois.

See all otolaryngology providers in Illinois

Medicare billing

Part B allowed, 2024
$55,419
Medicare patients
152
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab31$155,271
Azelastine Hcl36$1,575
Fluticasone Propionate32$495
Montelukast Sodium17$396
Famotidine19$198

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →